Clinical Course of Two Patients with COVID-19 Respiratory Failure After Administration of the Anticancer Small Molecule, RRx-001

Two critically ill COVID-19 infected patients, who had exhausted all available treatment options, were treated with the small-molecule RRx-001 with subsequent improvement. RRx-001, a first-in-class small molecule with anti-inflammatory, vascular normalizing and macrophage-repolarizing properties, has been safely administered 300+ patients in clinical trials. This is the first report of RRx-001 treatment of COVID-19.

Automated summary

This article presents the first report of RRx-001 treatment for COVID-19. Two critically ill patients with COVID-19, who had tried all available treatment options, showed improvement after receiving RRx-001. RRx-001 is a first-in-class small molecule with various properties and has been safely administered to over 300 patients in clinical trials.